Neurogene Inc (NGNE)

Currency in USD
26.090
-0.390(-1.47%)
Closed·
26.0900.000(0.00%)
·
NGNE is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
25.32027.010
52 wk Range
11.77037.266
Key Statistics
Prev. Close
26.48
Open
26.52
Day's Range
25.32-27.01
52 wk Range
11.77-37.266
Volume
106.33K
Average Vol. (3m)
174.83K
1-Year Change
108.6723%
Book Value / Share
17.1
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NGNE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
76.429
Upside
+192.94%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings upwards for the upcoming period

Neurogene Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 76.429
(+192.94% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Guggenheim
Buy69.00+164.47%-MaintainApr 28, 2026
Canaccord
Buy180.00+589.92%200.00MaintainApr 06, 2026
H.C. Wainwright
Buy70.00+168.30%-MaintainMar 26, 2026
William Blair
Buy---MaintainMar 24, 2026
Leerink Partners
Buy70.00+168.30%-MaintainMar 24, 2026

Neurogene Inc SWOT Analysis


Risk vs. Reward
Delve into Neurogene's SWOT analysis, balancing promising clinical data against regulatory hurdles and fierce competition in the evolving gene therapy landscape
Competitive Edge
Explore how Neurogene's EXACT platform technology could revolutionize treatments for multiple dosage-sensitive genetic disorders, extending beyond Rett syndrome
Financial Outlook
Despite negative EPS forecasts through 2025, Neurogene maintains a healthy cash position. Analysts set a $65 price target, indicating potential upside
Gene Therapy Pionee
Neurogene's NGN-401 shows promise in treating Rett syndrome, leveraging innovative gene therapy techniques to address a $2.5 billion market opportunity
Read full SWOT analysis

Earnings

Latest Release
Mar 24, 2026
EPS / Forecast
-1.12 / -1.25
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

NGNE Income Statement

Compare NGNE to Peers and Sector

Metrics to compare
NGNE
Peers
Sector
Relationship
P/E Ratio
−4.5x−4.4x−0.5x
PEG Ratio
−4.70−0.060.00
Price / Book
1.5x2.5x2.6x
Price / LTM Sales
-11.5x3.2x
Upside (Analyst Target)
165.0%74.6%50.8%
Fair Value Upside
Unlock−2.8%7.7%Unlock

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
2.69M17.20%71.14M
Other Institutional Investors
21.82M82.80%577.84M
Public Companies & Retail Investors
0.000.00%0.00
Total
24.51M100.00%648.98M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Samsara Biocapital, L.P.11.00%1,717,12745,470
Samsara BioCapital LLC11.00%1,717,12745,470

People Also Watch

81.91
VIK
+4.29%
42.12
TVTX
+5.04%
7.64
AIRO
+1.87%
9.190
RDW
+6.86%
123.14
SATS
+2.81%

FAQ

What Is the Neurogene (NGNE) Stock Price Today?

The Neurogene stock price today is 26.090 USD.

What Stock Exchange Does Neurogene Trade On?

Neurogene is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Neurogene?

The stock symbol for Neurogene is "NGNE."

What Is the Neurogene Market Cap?

As of today, Neurogene market cap is 408.900M USD.

What Is Neurogene's Earnings Per Share (TTM)?

The Neurogene EPS (TTM) is -4.237.

From a Technical Analysis Perspective, Is NGNE a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Neurogene Stock Split?

Neurogene has split 2 times.

How Many Employees Does Neurogene Have?

Neurogene has 131 employees.

What is the current trading status of Neurogene (NGNE)?

As of Apr 30, 2026, Neurogene (NGNE) is trading at a price of 26.090 USD, with a previous close of 26.480 USD. The stock has fluctuated within a day range of 25.320 USD to 27.010 USD, while its 52-week range spans from 11.770 USD to 37.266 USD.

What Is Neurogene (NGNE) Price Target According to Analysts?

The average 12-month price target for Neurogene is 76.429 USD, with a high estimate of 180 USD and a low estimate of 46 USD. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +192.94% Upside potential.

What Is the NGNE Premarket Price?

NGNE's last pre-market stock price is 24.500 USD. The pre-market share volume is 50.000, and the stock has decreased by -1.980, or -7.480%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.